FDA Extends Dupilumab COPD Decision to September 2024
The FDA moved the target date for their decision on the dupilumab application by 3 months, citing a need for more efficacy data from its pivotal phase 3 trials.
Surya Bhatt Smitht Surya Bhatt Lung Imaging Lab University Of Alabama At Birmingham Drug Administration Regeneron Pharmaceutical
Source: hcplive.com